BETTER
FASTER
ECONOMICAL

DIFFICULT CANCERS REQUIRE SMARTER STRATEGIES

  • Tumors have latent vulnerabilities that can be identified through ETA.
  • Agnostic to stage, grade, anatomy or morphology.
  • Integrational multi-analyte interrogation of tumor interactome and tumor function.
  • Tandem targeting of multiple vulnerabilities of the tumor using combination therapies to yield additive or synergistic benefits.

DIFFICULT CANCERS REQUIRE SMARTER STRATEGIES

  • Tumors have latent vulnerabilities that can be identified through ETA.
  • Agnostic to stage, grade, anatomy or morphology.
  • Integrational multi-analyte interrogation of tumor interactome and tumor function.
  • Tandem targeting of multiple vulnerabilities of the tumor using combination therapies to yield additive or synergistic benefits.
BETTER
FASTER
ECONOMICAL
SNVs/ INDELs
442 Genes
CNAs
417 Genes
FUSIONS
51 Genes
TMB
PDL1
MSI | MMR

Features

Targeted Therapy : Evaluation of companion diagnostic therapies across several cancer indications, and clinical trial matching across all solid tumors.
Immunotherapy : Helps inform immunotherapy decisions by including genomic signatures such as microsatellite instability (MSI), tumor mutational burden (TMB) and PDL1 status.
Simplified Report : All results are provided in a simplified report, with indications for approved therapies and genomic highlights.
452 Genes (SNVs, CNAs, Fusions and Indels).
Turnaround time is less than 3 working days from the day we receive the tissue sample.

Comparison

Platform Parameters FoundationOne CDx* Celldx
NGS Number of Genes 324 452
SNVs + Indels 309 442
SNAs 309 417
Fusions 36 51
TMB
MMR
HRD
IHC PD-L1
(optional)
STR | IHC MSI
Patient Benefits TAT 2 Weeks 48 Hours
Cost

* FoundationOne®CDx are registered trademarks of Foundation Medicine, Inc.

SNVs + INDELs

ARAFBRCA1BRCA2CDKN1BFANCIH3F3AHIST1H3BKNSTRNMAGOHMAXMED12NOTCH3POLERAC1RAD51RAD51BRAD51CRAD51DRHEBRHOARNF43SLX4SPOPSTAT3U2AF1

SNVs + INDELs + CNAs

ABL1ABL2ACVR2AADAMTS20AFF1AFF3AKAP9AKT1AKT2AKT3ALKAPCARARID1AARID2ARNTASXL1ATF1ATMATRATRXAURKAAURKBAURKCAXLBAI3BAP1BCL10BCL11ABCL11BBCL2BCL2L1BCL2L2BCL3BCL6BCL9BCRBIRC2BIRC3BIRC5BLMBLNKBMPR1ABRAFBRD3BRIP1BTKBUB1BCARD11CASC5CBLCCND1CCND2CCND3CCNE1CD79ACD79BCDC73CDH1CDH11CDH2CDH20CDH5CDK12CDK2CDK4CDK6CDK8CDKN2ACDKN2BCDKN2CCEBPACHEK1CHEK2CICCKS1BCMPK1COL1A1CRBNCREB1CREBBPCRKLCRTC1CSF1RCSMD3CTNNA1CTNNB1CYLDCYP2C19CYP2D6DAXXDCCDDB2DDIT3DDR2DEKDICER1DNMT3ADPYDDSTEGFREML4EP300EP400EPHA3EPHA7EPHB1EPHB4EPHB6ERBB2ERBB3ERBB4ERCC1ERCC2ERCC3ERCC4ERCC5ERGESR1ETS1ETV1ETV4EXT1EXT2EZH2FAM123BFANCAFANCCFANCD2FANCFFANCGFASFBXW7FGF19FGF3FGFR1FGFR2FGFR3FGFR4FHFLCNFLI1FLT1FLT3FLT4FN1FOXL2FOXO1FOXO3FOXP1FOXP4FZR1G6PDGATA1GATA2GATA3GDNFGNA11GNAQGNASGPR124GRM8GUCY1A2HCAR1HIF1AHLFHNF1AHOOK3HRASHSP90AA1HSP90AB1ICKIDH1IDH2IGF1RIGF2IGF2RIKBKBIKBKEIKZF1IL2IL21RIL6STIL7RING4IRF4IRS2ITGA10ITGA9ITGB2ITGB3JAK1JAK2JAK3JUNKAT6AKAT6BKDM5CKDM6AKDRKEAP1KITKLF6KRASLAMP1LCKLIFRLPHN3LPPLRP1BLTFLTKMAFMAFBMAGEA1MAGI1MALT1MAML2MAP2K1MAP2K2MAP2K4MAP3K7MAPK1MAPK8MARK1MARK4MBD1MCL1MDM2MDM4MEN1METMITFMLH1MLLMLL2MLL3MLLT10MMP2MN1MPLMRE11AMSH2MSH6MTORMTRMTRRMUC1MUTYHMYBMYCMYCLMYCL1MYCNMYD88MYH11MYH9NBNNCOA1NCOA2NCOA4NF1NF2NFE2L2NFKB1NFKB2NINNKX2-1NLRP1NOTCH1NOTCH2NOTCH4NPM1NRASNSD1NTRK1NTRK2NTRK3NUMA1NUP214NUP98PAK3PALB2PARP1PAX3PAX5PAX7PAX8PBRM1PBX1PDE4DIPPDGFBPDGFRAPDGFRBPER1PGAP3PHOX2BPIK3C2BPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIM1PKHD1PLAG1PLCG1PLEKHG5PMLPMS1PMS2POT1POU5F1PPARGPPP2R1APRDM1PRKAR1APRKDCPSIP1PTCH1PTENPTGS2PTPN11PTPRDPTPRTRAD50RAF1RALGDSRARARB1RECQL4RELRETRHOHRICTORRNASELRNF2RNF213ROS1RPS6KA2RRM1RUNX1RUNX1T1SAMD9SBDSSDHASDHBSDHCSDHDSEPT09SETD2SF3B1SGK1SH2D1ASMAD2SMAD4SMARCA4SMARCB1SMOSMUG1SOCS1SOX11SOX2SRCSSX1STK11STK36SUFUSYKSYNE1TAF1TAF1LTAL1TBX22TCF12TCF3TCF7L1TCF7L2TCL1ATERTTET1TET2TFE3TGFBR2TGM7THBS1TIMP3TLR4TLX1TNFAIP3TNFRSF14TNK2TOP1TP53TPRTRIM24TRIM33TRIP11TRRAPTSC1TSC2TSHRUBR5UGT1A1USP9XVHLWASWHSC1WRNWT1XPAXPCXPO1XRCC2ZNF384ZNF521

GENE FUSIONS

AKT2ALKARAXLBRAFBRCA1BRCA2CDKN2AEGFRERBB2ERBB4ERGESR1ETV1ETV4ETV5FGFR1FGFR2FGFR3FGRFLT3JAK2KRASMDM4METMYBMYBL1NF1NOTCH1NOTCH4NRG1NTRK1NTRK2NTRK3NUTM1PDGFRAPDGFRBPIK3CAPPARGPRKACAPRKACBPTENRAD51BRAF1RB1RELARETROS1RSPO2RSPO3TERT

DOWNLOAD BROCHURE + SAMPLE REPORT

PDF will be emailed

 

I have read and understood the terms of use and the privacy policy and I agree.

Terms and Conditions

On my request, Datar Cancer Genetics (DCG) has agreed to permit me to access and download a copy of the specimen Test Report for 'Celldx' on the following express conditions which I hereby declare are binding on me and also declare that but for such acceptance by me, DCG would not have permitted me to download and obtain printout of the said specimen report. I have read the Terms and Conditions set out below carefully and after full consideration and understanding my responsibility, and the fact that the information is provided to me for my bona fide personal use and made available in 'trust', I subscribe to the same as under:



Terms and Conditions:

  • I have correctly declared my true legal name in the information submitted at the time of my request.
  • That I am a person above the age of 18 years and legally competent to enter into a lawful and binding contract.
  • That I expressly recognize and do not dispute that DCG is the sole Copyright holder and Intellectual Property holder in respect of all contents in regard to the test procedure, the process of analysis, layout and contents of the Report, the design and artwork and all such other intangible and intellectual property of DCG which is materially related to the said Report and I undertake not to infringe and/or prejudicially use and/or disclose to any third person the said information / report / material particulars to the prejudice of DCG.
  • That I shall not directly or indirectly derive any commercial benefit from the said material so downloaded by me and/or any intellectual property related thereto.
  • I recognize and declare that in case of breach of any of the aforesaid express covenants and all the implied duties of a trustee, DCG would be entitled to both monetary and injunctive reliefs against me and I consent to passing an injunctive order against me in the event of infringement / breach of the aforesaid undertakings and declarations.
  • I solemnly declare as above.

CONTACT US

I have read and understood the terms of use and the privacy policy and I agree.